Shevroja Enisa, Lamy Olivier, Kohlmeier Lynn, Koromani Fjorda, Rivadeneira Fernando, Hans Didier
Center of Bone Diseases, Bone & Joint Department, Lausanne University Hospital, Lausanne, Switzerland; Musculoskeletal Genomics, Departments of Internal Medicine and Epidemiology, Rotterdam, The Netherlands.
Center of Bone Diseases, Bone & Joint Department, Lausanne University Hospital, Lausanne, Switzerland.
J Clin Densitom. 2017 Jul-Sep;20(3):334-345. doi: 10.1016/j.jocd.2017.06.019. Epub 2017 Jul 19.
Osteoporosis is a common bone disease characterized by low bone mass and altered bone microarchitecture, resulting in decreased bone strength with an increased risk of fractures. In clinical practice, physicians can assess the risk of fracture for a patient based on several risk factors. Some such as age, weight, and history of fractures after 50 years of age, parental fracture, smoking status, and alcohol intake are incorporated into FRAX, an assessment tool that estimates the 10-year probability of hip fracture and major osteoporotic fractures based on the individual's risk factors profile. The diagnosis of osteoporosis is currently based on bone mineral density (BMD) assessed by dual-energy X-ray absorptiometry scans. Among other widely recognized limitations of BMD is that BMD considers only the density of the bone and fails in measuring bone microarchitecture, for which novel techniques, such as trabecular bone score (TBS), have been developed. TBS is a texture parameter related to bone microarchitecture that may provide skeletal information that is not captured from the standard BMD measurement. Several studies have examined the value of TBS on predicting osteoporotic fractures. Our study aimed to summarize a review of the current scientific literature with focus on fracture risk assessment and to present both its findings and its conclusions regarding how and when TBS should be used. The existing literature indicates that low lumbar spine TBS is associated with a history of fracture and the incidence of new fracture. The effect is largely independent of BMD and of sufficient magnitude to enhance risk stratification with BMD. The TBS effect is also independent of FRAX, with likely greatest utility for those individuals whose BMD levels lie close to an intervention threshold. The clinical and scientific evidence supporting the use of TBS, with the ability of this technology to be seamlessly integrated into a daily workflow, makes TBS an attractive and useful clinical tool for physicians to improve patient management in osteoporosis. Further research is ongoing and necessary to further clarify the role of TBS in additional specific disorders.
骨质疏松症是一种常见的骨骼疾病,其特征为骨量低和骨微结构改变,导致骨强度下降,骨折风险增加。在临床实践中,医生可根据多种风险因素评估患者的骨折风险。其中一些因素,如年龄、体重、50岁后骨折史、父母骨折史、吸烟状况和酒精摄入量,已被纳入FRAX,这是一种评估工具,可根据个体风险因素概况估算髋部骨折和主要骨质疏松性骨折的10年概率。目前,骨质疏松症的诊断基于双能X线吸收法扫描评估的骨密度(BMD)。BMD的其他广泛认可的局限性包括,BMD仅考虑骨密度,无法测量骨微结构,为此已开发出小梁骨评分(TBS)等新技术。TBS是一种与骨微结构相关的纹理参数,可能提供从标准BMD测量中无法获取的骨骼信息。多项研究探讨了TBS在预测骨质疏松性骨折方面的价值。我们的研究旨在总结当前科学文献综述,重点关注骨折风险评估,并阐述其关于TBS应如何以及何时使用的研究结果和结论。现有文献表明,低腰椎TBS与骨折史和新发骨折发生率相关。这种影响在很大程度上独立于BMD,且程度足以增强BMD的风险分层。TBS的影响也独立于FRAX,对于那些BMD水平接近干预阈值的个体可能最有用。支持使用TBS的临床和科学证据,以及该技术能够无缝融入日常工作流程,使TBS成为医生改善骨质疏松症患者管理的一种有吸引力且有用的临床工具。正在进行且有必要进行进一步研究,以进一步阐明TBS在其他特定疾病中的作用。